Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

About this update from Abeona Therapeutics Inc.

[{"type":"text","content":"CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona’s Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona’s continued focus on strengthening its leadership team to advance both strategic and financial objectives. “On behalf of the Board, we are delighted to welcome Keith to Abeona,” said Michael Amoroso, Chairman of Abeona’s Board of Directors. “Keith’s deep experience in capital markets, corporate development, and operational scaling will be an invaluable voice as we continue to position Abeona for growth as a commercial-stage biotech company.” Mr. Goldan is an accomplished financial leader, currently serving as Chief Financial Officer of Syndax Pharmaceuticals since 2022 where he has provided leadership through their first two product approvals and commercialization. Prior to his current role, Mr. Goldan served as Chief Financial Officer of Optinose, a publicly traded specialty pharmaceutical company, where he played a key role in building the infrastructure to support the successful US launch of its lead product. Prior to Optinose, he was Chief Financial Officer and Senior Vice President of Fibrocell, a publicly traded cell and gene therapy company. Mr. Goldan also held Chief Financial Officer roles at NuPathe, PuriCore plc and Biosyn, and served in the financial leadership positions at ViroPharma and KPMG. Across these roles, he led finance, accounting, IT, HR and corporate development functions; successfully raised capital through multiple IPOs, capital market transactions and related financing vehicles; and executed several merger and acquisition transactions. “I am excited to join the Board of Directors at Abeona at this important time in the organization’s growth as commercial momentum continues to build for its first US launch,” said Mr. Goldan. “I look forward to partnering with the talented leadership team at Abeona to advance strategic priorities and drive value for patients and shareholders.” About Abeona Therap...

More updates from Abeona Therapeutics Inc.